Let-7c Inhibits Cholangiocarcinoma Growth but Promotes Tumor Cell Invasion and Growth at Extrahepatic Sites
Overview
General Medicine
Authors
Affiliations
Cholangiocarcinoma (CCA) is a cancer type with high postoperative relapse rates and poor long-term survival largely due to tumor invasion, distant metastasis, and multidrug resistance. Deregulated microRNAs (miRNAs) are implicated in several cancer types including CCA. The specific roles of the miRNA let-7c in cholangiocarcinoma are not known and need to be further elucidated. In our translational study we show that microRNA let-7c expression was significantly downregulated in human cholangiocarcinoma tissues when compared to adjacent tissues of the same patient. Let-7c inhibited the tumorigenic properties of cholangiocarcinoma cells including their self-renewal capacity and sphere formation in vitro and subcutaneous cancer cell growth in vivo. Ectopic let-7c overexpression suppressed migration and invasion capacities of cholangiocarcinoma cell lines in vitro, however, promoted distant invasiveness in vivo. Furthermore, we found that let-7c regulated the aforementioned malignant biological properties, at least in part, through regulation of EZH2 protein expression and through the DVL3/β-catenin axis. The miRNA let-7c thus plays an important dual role in regulating tumorigenic and metastatic abilities of human cholangiocarcinoma through mechanisms involving EZH2 protein and the DVL3/β-catenin axis.
Fagoonee S, Weiskirchen R Cells. 2024; 13(23).
PMID: 39682684 PMC: 11640337. DOI: 10.3390/cells13231935.
Peng F, Feng Y, Yu S, He R, Wang H, Xie Y PLoS One. 2024; 19(12):e0314609.
PMID: 39671359 PMC: 11642946. DOI: 10.1371/journal.pone.0314609.
Zhou C, Wang W, Mu Y, Meng M Front Immunol. 2024; 15:1393404.
PMID: 39206183 PMC: 11349560. DOI: 10.3389/fimmu.2024.1393404.
Liu C, Yu C, Song G, Fan X, Peng S, Zhang S BMC Genomics. 2023; 24(1):724.
PMID: 38036953 PMC: 10688136. DOI: 10.1186/s12864-023-09635-4.
Lucarini V, Nardozi D, Angiolini V, Benvenuto M, Focaccetti C, Carrano R Biomedicines. 2023; 11(6).
PMID: 37371856 PMC: 10296425. DOI: 10.3390/biomedicines11061761.